Halozyme Therapeutics reported $117.62M in Ordinary Share Capital for its fiscal quarter ending in June of 2025.


Ordinary Share Capital Change Date
Acadia Pharmaceuticals USD 167.36M 167.35M Jun/2025
Agios Pharmaceuticals USD 58.04M 57.96M Jun/2025
Alnylam Pharmaceuticals USD 130.98M 129.67M Jun/2025
Amarin USD 308.15M 2.85M Mar/2025
Amgen USD 538M 33.04B Jun/2025
Baxter International USD 683M 0 Dec/2024
Cytokinetics USD 119.6M 119.48M Jun/2025
DBV Technologies USD 136.76M 125.11M Jun/2025
Eli Lilly USD 946.83M 354.23M Jun/2025
Halozyme Therapeutics USD 117.62M 117.5M Jun/2025
Ionis Pharmaceuticals USD 159.2M 159.04M Jun/2025
MannKind USD 306.33M 303.29M Jun/2025
Pfizer USD 5.68B 5.2B Jun/2025
United Therapeutics USD 45.22M 44.42M Jun/2025